Story

Nexperia China Shifts to Domestic 12-Inch Wafers After European Supply Cutoff

ENTHMSVIIDZHZH-TWJAKOHI
Sep 20, 20262 min read
Nexperia China Shifts to Domestic 12-Inch Wafers After European Supply Cutoff

Summary

Following the disruption of nearly 59,000 wafers per month from its European fabs, Nexperia China has successfully pivoted to a domestic 12-inch foundry partner to secure its production and target growth in the automotive and AI sectors.

Text size
Background

Nexperia China has re-engineered its supply chain over the past year, shifting production to a domestic 12-inch wafer platform after its access to European fabrication plants was severed. The move was a critical response to a supply disruption that threatened to idle its vast backend assembly and test operations in China.

Supply Chain Disruption

According to a report from Time Weekly, Nexperia's previously integrated global supply chain was fractured in the second half of 2025. Actions by the Dutch government reportedly restricted parent company Wingtech Technology's control over Nexperia's Dutch entity, effectively splitting the Chinese and European operations.

This cutoff directly impacted Nexperia China's access to its primary frontend manufacturing facilities. The company lost its supply from two key European fabs, which together produced approximately 59,000 8-inch equivalent wafers per month:

  • Hamburg, Germany: Over 35,000 wafers per month (8-inch equivalent).
  • Manchester, UK: Roughly 24,000 wafers per month (8-inch equivalent).

The disruption posed a significant risk to Nexperia's Dongguan plant in China, which handles about 70% of the company's global assembly and testing capacity.

The Pivot to 12-Inch Domestic Production

Sample IUX Markets – In-articleAd

Instead of waiting for the original supply chain to be restored, Nexperia China established a new manufacturing framework domestically. A source close to the company told Time Weekly that Nexperia China began work on alternative wafer solutions in the fourth quarter of 2025 and secured a partnership with a Chinese strategic partner by the end of the first quarter of 2026.

This partner operates China's first 12-inch automotive-grade power semiconductor wafer fab. The facility currently has a monthly capacity of 36,000 12-inch wafers (equivalent to about 81,000 8-inch wafers) and plans to expand to 50,000 wafers per month by the end of 2026. The transition to a modern, fully automated 12-inch platform offers advantages in production efficiency, unit cost, and product consistency compared to the older 6-inch and 8-inch lines.

By August, Nexperia China had already launched new products based on the 12-inch platform, including T2X series low-voltage MOSFETs and eighth-generation FS8 IGBTs. The company has also reportedly mass-produced over 1,300 different logic chip part numbers on the new platform.

Strategic Implications for Investors

This strategic shift allows Nexperia China to secure its core business, particularly in the automotive sector, where over 90% of its products are automotive-grade. Supply continuity for MOSFET and logic products is reportedly improving, with transistor supply expected to normalize in the second half of 2026.

Beyond stabilizing its existing operations, the move to a domestic 12-inch fab positions the company to capture new growth opportunities. These include the rising semiconductor demand from new energy vehicles (NEVs) and advanced driver-assistance systems (ADAS). Furthermore, Nexperia China is targeting the AI sector, not by producing AI processors, but by supplying the critical power management semiconductors (MOSFETs, protection devices) required for power-hungry AI servers and PCs.

Read next

More on Stocks
Shenzhen-Listed Jingxin Pharmaceutical Refiles for Hong Kong IPO

Stocks

Shenzhen-Listed Jingxin Pharmaceutical Refiles for Hong Kong IPO

Sep 20, 2026

Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ) has resubmitted its application for a main board listing on the Hong Kong Stock Exchange, aiming to secure a dual listing to access international capital. The company specializes in drugs for central nervous system and cardiovascular diseases.

Back to latest news

LATEST